Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809803 | 0.87 | GPR119 (0.53) | GPR119PIK3CD | |
| SCHEMBL3733175 | 0.80 | GPR119 (0.61) | GPR119PIK3CD | |
| SCHEMBL392033 | 0.78 | GPR119 (1.00) | GPR119PIK3CD | |
| SCHEMBL386526 | 0.76 | GPR119 (0.80) | GPR119PIK3CD | |
| SCHEMBL389616 | 0.76 | GPR119 (0.77) | GPR119 | |
| SCHEMBL15729087 | 0.74 | PIK3CD (1.00) | GPR119PIK3CD | |
| SCHEMBL15718699 | 0.74 | PIK3CD (1.00) | GPR119PIK3CD | |
| SCHEMBL391340 | 0.72 | GPR119 (1.00) | GPR119 | |
| SCHEMBL15728933 | 0.72 | PIK3CD (0.77) | PIK3CD | |
| SCHEMBL12236405 | 0.72 | GPR119 (0.62) | GPR119PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803754-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | GPR119 2/4885PIK3CD 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.